Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

被引：0
|
作者：
Killion, Lisa [1 ]
Alsharqi, Ali [1 ]
Kirby, Brian [1 ]
机构：
[1] St Vincents Hosp, Dublin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad113.113
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P85
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Switching from biosimilar adalimumab to originator adalimumab and vice versa as an alternative to target switch in patients with hidradenitis suppurativa: a single center experience
    Roldan, Fernando Alfageme
    Cembrero, Hirune
    Salguero, Irene
    Martinez, Constanza
    Roustan, Gaston
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 92 - 92
  • [22] Switching from originator infliximab to biosimilar: Missed dose and discontinuation in a population-based cohort
    Moura, Cristiano S.
    Curtis, Jeffrey R.
    Choquette, Denis
    Boire, Gilles
    Bykerk, Vivian P.
    Maksymowych, Walter P.
    Lakatos, Peter L.
    Afif, Waqqas
    Bernatsky, Sasha
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 19 - 20
  • [23] Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
    Jose Casanova, Maria
    Nantes, Oscar
    Varela, Pilar
    Vela-Gonzalez, Milagros
    Rivero, Montserrat
    Sierra-Gabarda, Olivia
    Riestra, Sabino
    Barreiro-de Acosta, Manuel
    del Mar Martin-Rodriguez, Maria
    Jerusalen Gargallo-Puyuelo, Carla
    Reygosa, Cristina
    Munoz, Roser
    Garcia de la Filia-Molina, Irene
    Nunez-Ortiz, Andrea
    Kolle, Lilyan
    Calafat, Margalida
    Maria Huguet, Jose
    Iglesias-Flores, Eva
    de Jesus Martinez-Perez, Teresa
    Bosch, Orencio
    Maria Duque-Alcorta, Jose
    Frago-Larramona, Santiago
    Van Domselaar, Manuel
    Manuel Gonzalez-Cosano, Victor
    Bujanda, Luis
    Rubio, Saioa
    Mancebo, Alejo
    Castro, Beatriz
    Garcia-Lopez, Santiago
    de Francisco, Ruth
    Nieto-Garcia, Laura
    Laredo, Viviana
    Gutierrez-Casbas, Ana
    Mesonero, Francisco
    Leo-Carnerero, Eduardo
    Canete, Fiorella
    Ruiz, Lucia
    Gros, Beatriz
    del Moral-Martinez, Maria
    Rodriguez, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (01) : 60 - 70
  • [24] Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre
    Gallo, Giuseppe
    Rostagno, Elisabetta
    Siliquini, Niccolo
    Stroppiana, Elena
    Verrone, Anna
    Ortoncelli, Michela
    Quaglino, Pietro
    Dapavo, Paolo
    Ribero, Simone
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 (03) : E431 - E432
  • [25] Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response: Data from the German HS registry HSBEST
    Ohm, Frenz
    Kirsten, Natalia
    Gehrdau, Kathrin
    Stephan, Brigitte
    Ben-Anaya, Nesrine
    Pinter, Andreas
    Bechara, Falk G.
    Presser, Dagmar
    Zouboulis, Christos C.
    Augustin, Matthias
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 24 - 25
  • [26] A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS
    Ng, C. R.
    Samec, S.
    Kavanagh, P.
    Mccarthy, G.
    Donnelly, S.
    Wilson, A. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1427 - 1427
  • [27] The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine
    Fisher, Anat
    Kim, Jason D.
    Dormuth, Colin
    CLINICAL THERAPEUTICS, 2022, 44 (07) : 957 - +
  • [28] Real-world safety of switching from originator to biosimilar natalizumab
    Brustad, Age Winje
    Hogestol, Einar
    Meling, Martine
    Celius, Elisabeth Gulowsen
    Berg-Hansen, Pal
    Konig, Marton
    Holterbakken, Trine Alm
    Warren, David
    Gehin, Johanna
    Bolstad, Nils
    Nygaard, Gro Owren
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1056 - 1057
  • [29] SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY IN A COHORT OF PATIENTS WITH ESTABLISHED BEHCET'S DISEASE
    Venerito, V.
    Lopalco, G.
    Cantarini, L.
    Fabiani, C.
    Nivuori, M.
    Cacciapaglia, F.
    Galeazzi, M.
    Lapadula, G.
    Iannone, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1494 - 1495
  • [30] Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study
    Ribaldone, Davide Giuseppe
    Tribocco, Elisa
    Rosso, Chiara
    Armandi, Angelo
    Vernero, Marta
    Bugianesi, Elisabetta
    Astegiano, Marco
    Saracco, Giorgio Maria
    Caviglia, Gian Paolo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
12345